Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen

PLoS Neglected Tropical Diseases

Volumn 3, Issue 11, 2009, Pages

  Sharlow, Elizabeth R ^a,b   Close, David ^a   Shun, Tongying ^a   Leimgruber, Stephanie ^a   Reed, Robyn ^a   Mustata, Gabriela ^a   Wipf, Peter ^a   Johnson, Jacob ^c   O'Neil, Michael ^c   Grögl, Max ^c   Magill, Alan J ^c   Lazo, John S ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIVICIN; AMPHOTERICIN B; ANTIPROTOZOAL AGENT; APHIDICOLIN; CID 16187595; CID 2851545; CID 2946668; CID 728862; CID 742546; CID 757789; CID 760847; CID 786799; CLOTRIMAZOLE; DISULFIRAM; PENTAMIDINE ISETHIONATE; PHENYLTOLOXAMINE; SANGIVAMYCIN; UNCLASSIFIED DRUG;

ALGORITHM; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL STRAIN; CELL VIABILITY; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; EXPERIMENTAL MOUSE; FOOT PAD; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA MAJOR; LEISHMANIASIS; PROMASTIGOTE; BIOLOGY; CELL LINE; DRUG EFFECT; DRUG SCREENING; EVALUATION; GROWTH, DEVELOPMENT AND AGING; METHODOLOGY; MOLECULAR LIBRARY; PARASITOLOGY; SKIN LEISHMANIASIS;

ANTIPROTOZOAL AGENTS; CELL LINE; COMPUTATIONAL BIOLOGY; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; PARASITIC SENSITIVITY TESTS; SMALL MOLECULE LIBRARIES;

EID: 73449120692     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000540     Document Type: Article

References (77)

1. Ameen M (2007) Cutaneous leishmaniasis: therapeutic strategies and future directions. Expert Opin Pharmacother 8: 2689-2699.
2. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C (2004) Treatment of cutaneous leishmaniasis among travelers. J Antimicrob Chemother 53: 158-166.
3. Shaw J (2007) The leishmaniasis-survival and expansion in a changing world. A mini-review. Mem Inst Oswaldo Cruz 102: 541-547.
4. Neuber H (2008) Leishmaniasis. J Dtsch Dermatol Ges 9: 754-765.
5. Ready PD (2008) Leishmaniasis emergence and climate change. Rev Sci Tech 27: 399-412.
6. Roberts LJ, Handman E, Foote SJ (2000) Leishmaniasis. BMJ 321: 801-804.
7. Leishmaniasis epidemic hits Afghanistan (2002) CMAJ 167: 536.
8. Stephenson J (2004) Leishmaniasis epidemic. JAMA 292: 1294.
9. Hotez P (2008) Neglected infections of poverty in the United States of America. PLoS Negl Trop Dis 2: e256. doi:10.1371/journal.pntd.0000256.
10. Cardo LJ (2006) Leishmania: risk to the blood supply. Transfusion 46: 1641-1645.
11. Alvar J, Yactayo S, Bern C (2006) Leishmaniasis and poverty. Trends Parasitol 22: 552-557.
12. Engels D, Savioli L (2006) Reconsidering the underestimated burden caused by neglected tropical diseases. Trends Parasitol 22: 363-366.
13. Bern C, Maguire JH, Alvar J (2008) Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2: e313. doi:10.1371/ journal.pntd.0000313.
14. Stuart R, Brun R, Croft S, Fairlamb A, Gürtler, et al. (2008) Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest 118: 1301-1310.
15. Hotez PJ, Fenwick A, Savioli L, Molyneux DH (2009) Rescuing the bottom billion through control of neglected tropical diseases. Lancet 373: 1570-1575.
16. Singh S, Sivakumar R (2004) Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother 10: 307-315.
17. Davis AJ, Kedzierski L (2005) Recent advances in antileishmanial drug development. Curr Opin Invest Drugs 6: 163-169.
18. Croft SL, Seifert K, Yardley V (2006) Current scenario of drug development for leishmaniasis. Ind J Med Res 123: 399-410.
19. Naderer T, Wee E, McConville MJ (2008) Role of hexosamine biosynthesis in Leishmania growth and virulence. Mol Micro 69: 858-869.
20. Lesho EP, Wortmann G, Neafie R, Aronson N (2005) Nonhealing skin lesions in a sailor and a journalist returing from Iraq. Cleve Clin J Med 72: 93-106.
21. Herwaldt BL, Berman JD (1992) Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 46: 296-306.
22. Berman JD (1988) Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis 10: 560-586.
23. Kandil E (1973) Treatment of cutaneous leishmaniasis with trimethoprim-sulfamethoxazole combination. Dermatologica 146: 303-309.
24. Marsden PD, Cuba CC, Barreto AC, Sampaio RN, Rocha RA (1979) Nifurtimox in the treatment of South American leishmaniasis. Trans R Soc Trop Med Hyg 73: 391-394.
25. Even-Paz Z, Weinrauch L, Livshin R, El-On J, Greenblatt CL (1982) Rifampicin treatment of cutaneous leishmaniasis. Int J Dermatol 21: 110-112.
26. Hossain MZ (1988) Combination therapy (monomycine and methyluracil) in leishmaniasis cutis. Int J Dermatol 27: 720-722.
27. Masmoudi A, Dammak A, Chaaben H, Maalej N, Akrout F, et al. (2008) Doxycycline for the treatment of cutaneous leishmaniasis. Dermatol Online J 14: 22.
28. Miguel DC, Yokoyama-Yasunaka JK, Uliana SR (2008) Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice. PLoS Negl Trop Dis 2: e249. doi:10.1371/journal.pntd.0000249.
29. Miguel DC, Zauli-Nascimento RC, Yokoyama-Yasunaka JK, Katz S, Barbiéri CL, et al. (2009) Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J Antimicrob Chemother 63: 365-368.
30. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, et al. (2005) The genome of the kinetoplastid parasite, Leishmania major. Science 309: 436-442.
31. Naula C, Parsons M, Mottram JC (2005) Protein kinases as drug targets in trypanosomes and Leishmania. Biochim Biophys Acta 1754: 151-159.
32. Peacock CS, Seeger K, Harris D, Murphy L, Ruiz JC, et al. (2007) Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat Gen 39: 839-847.
33. Croft SL, Coombs GH (2003) Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19: 502-508.
34. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2006) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Disc 6: 29-40.
35. Gerpe A, Aguirre G, Boiani L, Cerecetto H, Gonzalez M, et al. (2006) Indazole N- oxide derivatives as antiprotozoal agents: synthesis, biological evaluation and mechanism of action studies. Bioorg Med Chem 14: 3467-3480.
36. de Souza R, Pereira VLP, Muzitano MF, Falcao CAB, Rossi-Bergmann, et al. (2007) High selective leishmanicidal activity of 3-hydroxy-2-methylene-3-(4- bromophenyl)propanenitrile and analogous compounds. Eur J Med Chem 42: 99-102.
37. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, et al. (2007) High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 3: 466-479.
38. Tierno MB, Johnston PA, Foster C, Skoko JJ, Shinde SN, et al. (2007) Development and optimization of high-throughput in vitro protein phosphatase screening assays. Nat Protocol 2: 1134-1144.
39. Sharlow ER, Leimgruber S, Yellow-Duke A, Barrett R, Wang QJ, et al. (2008) Development, validation and implementation of immobilized metal affinity for phosphochemicals (IMAP)-based high throughput screening assays for low-molecular-weight compound libraries. Nat Protoc 3: 1350-6133.
40. Callahan HL, Portal AC, Devereaux R, Grögl M (1997) An axenic amastigote system for drug screening. Antimicrob Agents Chem 41: 818-822.
41. Yardley V, Croft SL (2000) A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 13: 243-248.
42. Kayser O, Keiderlen AF, Bertels S, Siems K (2001) Antileishmanial activities of aphodicolin and its semisynthetic derivatives. Antimicrob Agents Chemother 45: 288-292.
43. Mikus D, Steverding D (2000) A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar blue. Parasitol Int 48: 265-269.
44. Fumarola L, Spinelli R, Brandonisio O (2004) In vitro assays for evaluation of drug activity against Leishmania spp. Res Microbiol 155: 224-230.
45. Buckner FS, Wilson AJ (2005) Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. Am J Trop Med Hyg 72: 600-605.
46. Al-Bashir NT, Rassam MB (1992) Axenic cultivation of amastigotes of Leishmania donovani and Leishmania major and their infectivity. Ann Trop Med Parasitol 86: 487-502.
47. Bates PA (1993) Axenic culture of Leishmania amastigotes. Parasitol Today 9: 143-146.
48. Gupta N, Goyal N, Rastogi AK (2001) In vitro cultivation and characterization of axenic amastigotes of Leishmania. Trends Parasitol 17: 150-153.
49. Habibi P, Sadjjadi SM, Owji M, Moattari A, Sarkari B, et al. (2008) Characterization of in vitro cultivated amastigote like of Leishmania major: a substitution for in vivo studies. Iran J Parasitol 3: 6-15.
50. Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4: 67-73.
51. Jarvis RA, Patrick EA (1973) Clustering Using a Similarity Measure Based on Shared Near Neighbors. IEEE Trans Comput C-22: 1025-34.
52. ADME Boxes v4.0. http://pharma-algorithms.com/. Accessed 8 January 2009.
53. Japertas P, Didziapetris R, Petrauskas A (2003) Fragmental methods in the analysis of biological activities of diverse compound sets. Mini Rev Med Chem 3: 797-808.
54. Al-Khateeb GH, Al-Azawi DM (1981) A monophasic liquid medium (GD-NRC) for the cultivation of Leishmania donovani. J Parasitol 67: 127.
55. Sereno D, Lemesre JL (1997) Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agent Chemotherapy 41: 972-976.
56. Berman JD, Lee LS (1983) Activity of oral drugs against Leishmania tropica in human macrophages in vitro. Am J Trop Med Hyg 32: 947-951.
57. Rasheid KA, Morsy TA (1998) Efficacy of ivermectin on the infectivity of Leishmania major promastigotes. J Egypt Soc Parasitol 28: 207-212.
58. Larbi EB, al-Khawajah A, al-Gindan Y, Jain S, Abahusain A, et al. (1995) A randomized, double-blind, clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia. Am J Trop Med Hyg 52: 166-168.
59. Datta G, Bera T (2000) The effects of clofazimine, niclosamide and amphotericin B, on electron transport of Leishmania donovani promastigotes. Ind J Med Res 112: 15-20.
60. Chibale K, Haupt H, Kendrick H, Yardley V, Saravanamuthu A, et al. (2001) Antiprotozoal and cytotoxicity evaluation of sulfonamide and urea analogues of quinacrine. Bioorg Med Chem Lett 11: 2655-2657.
61. Berman JD, Webster HK (1982) In vitro effects of mycophenolic acid and allopurinol against Leishmania tropica in human macrophages. Antimicrob Agents Chemother 21: 887-891.
62. Vennerstrom JL, Lovelace JK, Waits VB, Hanson WL, Klayman DL (1990) Berberine derivatives as antileishmanial drugs. Antimicrob Agents Chemother 34: 918-921.
63. Mukherjee T, Roy K, Bhaduri A (1990) Acivicin: a highly active potential chemotherapeutic agent against visceral leishmaniasis. Biochem Biophys Res Comm 170: 426-432.
64. Mesa-Valle CM, Castilla-Calvente J, Sanchez-Moreno J, Moraleda-Lindez V, Barbe J, et al. (1996) Activity and mode of action of acridine compounds against Leishmania donovani. Antimicrob Agents Chemother 40: 684-690.
65. da Silva LE, Joussef AC, Pacheco LK, da Silva DG, Steindel M, et al. (2007) Synthesis and in vitro evaluation of leishmanicidal and trypanocidal activities of N-quinoli-8-yl-arylsulfonamides. Bioorg Med Chem 15: 7553-7560.
66. Lazo JS (2008) Rear-view mirrors and crystal balls: a brief reflection on drug discovery. Mol Interv 8: 60-3.
67. St. George S, Bishop JV, Titus RG, Selitrennikoff CP (2006) Novel Compounds Active against Leishmania major. Antimicrob Agents Chemother 50: 474-479.
68. Murray HW, Delph-Etienne S (2000) Roles of Endogeneous Gamma Interferon and Macrophage Microbicidal Mechanism in Host Response to Chemotherapy in Experimental Visceral Leishmaniasis. Infect Immun 68: 288-293.
69. Toledo VPCP, MayrinkW, Gollob KJ, Oliveirs MAP, da Costa CA, et al. (2001) Immunochemotherapy in American Cutaneous Leishmaniasis: Immunological aspects before and after treatment. Mem Inst Oswaldo Cruz 96: 89-98.
70. Parker KL, Rice DA, Lala DS, Ikeda Y, Luo X, et al. (2002) Steroidogenic factor 1: an essential mediator of endocrine development. Recent Prog Horm Res 57: 19-36.
71. Eckerdt F, Strebhardt K (2006) Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res 66: 6895-6898.
72. Wang QJ (2006) PKD at the crossroads of DAG and PKC signaling. Trends Pharm Sci 27: 317-323.
73. Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C, et al. (2002) Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther 1: 1255-1264.
74. Loomis CR, Bell RM (1988) Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. J Biol Chem 263: 1682-1692.
75. de Mendonca RL, Bouton D, Bertin B, Escriva H, Noel C, et al. (2002) A functionally conserved member of the FTZ-F1 nuclear receptor family from Schistosoma mansoni. Eur J Biochem 269: 5700-11.
76. Parsons M, Worthey EA, Ward PN, Mottram JC (2005) Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi. BMC Genomics 6: 127-145.
77. Brenchley R, Tariq H, McElhinney H, Szöor B, Huxley-Jones J, et al. (2007) The TriTryp Phosphatome: analysis of the protein phosphatase catalytic domains. BMC Genomics 8: 434-456.